Published in Int J Cancer on September 01, 2001
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45
Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res (2009) 1.22
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol (2012) 1.12
Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma. J Proteomics Bioinform (2013) 1.07
Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer (2005) 1.04
Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species. PLoS One (2012) 0.98
Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer (2008) 0.97
Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) (2010) 0.93
Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother (2008) 0.92
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia (2006) 0.89
Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. J Cancer (2015) 0.87
Melanoma resistance to photodynamic therapy: new insights. Biol Chem (2013) 0.86
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J Proteome Res (2013) 0.82
Erdr1 Suppresses Murine Melanoma Growth via Regulation of Apoptosis. Int J Mol Sci (2016) 0.82
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep (2016) 0.82
Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys (2014) 0.81
Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter. Invest New Drugs (2010) 0.79
Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. Lasers Med Sci (2013) 0.77
The metabolic bioactivation of caffeic acid phenethyl ester (CAPE) mediated by tyrosinase selectively inhibits glutathione S-transferase. Chem Biol Interact (2011) 0.76
Roles of Erythroid Differentiation Regulator 1 (Erdr1) on Inflammatory Skin Diseases. Int J Mol Sci (2016) 0.75
αNAC inhibition of the FADD-JNK axis plays anti-apoptotic role in multiple cancer cells. Cell Death Dis (2014) 0.75
Automated dermoscopy image analysis of pigmented skin lesions. Cancers (Basel) (2010) 0.75
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells. Drug Des Devel Ther (2016) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Human mast cells produce IL-8. J Immunol (1993) 1.44
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood (1999) 1.21
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
The polymerase chain reaction. Method and applications in dermatopathology. Am J Dermatopathol (1993) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol (2001) 0.96
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther (1998) 0.95
Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer (2000) 0.93
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele. J Eur Acad Dermatol Venereol (2010) 0.92
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol (2004) 0.91
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer (2000) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J (2000) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics (2006) 0.88
Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient. Transplant Proc (2012) 0.88
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol (2014) 0.88
Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun (1995) 0.88
β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur J Cancer (2013) 0.87
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer (1999) 0.86
Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett (2001) 0.86
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol (2000) 0.86
Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol (1995) 0.86
The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol (1998) 0.85
High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer (2000) 0.85
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol (2006) 0.85
Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis (1999) 0.84
Expression of c-Met in developing rat hippocampus: evidence for HGF as a neurotrophic factor for calbindin D-expressing neurons. Eur J Neurosci (2000) 0.84
Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie (2003) 0.84
Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res (1998) 0.84
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol (2014) 0.84
Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer (2000) 0.83
Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch (1996) 0.83
Expression of growth factor receptors on human melanoma cells: comparison of modulating effects of interferons and retinoids. Exp Dermatol (1993) 0.82
Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II. J Eur Acad Dermatol Venereol (2011) 0.82
CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopathol (1998) 0.82
Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department. J Eur Acad Dermatol Venereol (2010) 0.81
Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods (1998) 0.81
Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. J Invest Dermatol (2000) 0.81
Expression of CD44 variant isoforms in malignant melanoma. Clin Cancer Res (1996) 0.81
Interferon-gamma downregulates epidermal growth factor receptors on human melanoma cells. Exp Dermatol (1995) 0.81
Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res (2000) 0.80
Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter. Br J Cancer (1995) 0.80
Cell-based vaccination against melanoma--background, preliminary results, and perspective. J Mol Med (Berl) (1999) 0.80
Radio-guided surgery: advantages of a new portable γ-camera (Sentinella) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies. J Eur Acad Dermatol Venereol (2011) 0.79
Comparison of non-viral transfection methods in melanoma cell primary cultures. Cytokine (2000) 0.79
Multicentre study on standardisation of melanoma cell culture--an initiative of the German Melanoma Research Network. Pigment Cell Melanoma Res (2010) 0.79
Verrucous cysts: histopathologic characterization and molecular detection of human papillomavirus-specific DNA. J Cutan Pathol (1993) 0.79
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. Cytogenet Cell Genet (1999) 0.79
Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol (2010) 0.79
Enhanced P-selectin expression in chronic and dermographic urticaria. Int Arch Allergy Immunol (1997) 0.79
Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype. Melanoma Res (1993) 0.79
Investigation of adhesion of modern wound dressings: a comparative analysis of 56 different wound dressings. J Eur Acad Dermatol Venereol (2010) 0.78
Systemic treatment in advanced melanoma: innovative perspectives. Onkologie (2003) 0.78
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol (2007) 0.78
Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. Br J Cancer (1994) 0.78
Interleukin-7. Biology and implications for dermatology. Exp Dermatol (1996) 0.78
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp Dermatol (1994) 0.78
[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology]. Dtsch Med Wochenschr (2010) 0.78
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol (2011) 0.78
Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol (1995) 0.78
Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment. Onkologie (2004) 0.78
Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. Br J Dermatol (2003) 0.77
Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol (1995) 0.77
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther (1998) 0.77
[Clear cell tumor of the lung]. Pathologe (2005) 0.77
Surveillance and follow-up examinations in cutaneous melanoma. Onkologie (2003) 0.76